A protonpumpagátlók az utóbbi évtizedekben a savfüggő kórképek kezelésének élvonalbeli gyógyszereivé váltak. Megkérdőjelezhetetlen hatékonyságuk ellenére azonban ezek a szerek nem veszélytelenek, az utóbbi időszakban számos közlemény született hosszú távú mellékhatásaikkal kapcsolatban. A felmerült lehetséges mellékhatások között a csonttörések fokozott kockázata, a csökkent B12-vitamin-, illetve magnéziumszint, valamint a Clostridium difficile-fertőzés emelhető ki. Tekintettel arra, hogy a protonpumpagátlók világszerte egyre nagyobb számban kerülnek felírásra, nagyon fontos a tartós szedésük következtében fellépő mellékhatások ismerete mind a szakorvosok, mind az alapellátásban dolgozó orvosok számára. A szerzők ebben az összefoglaló közleményben a protonpumpagátlók hosszú távú lehetséges mellékhatásait ismertetik, hangsúlyozva azt, hogy ezeket a szereket csak megfelelő, szigorú indikációval szabad tartósan alkalmazni. Orv Hetil. 2018; 159(19): 735–740.
Rotman S, Bishoop T. Proton pump inhibitor use in the US ambulatory setting, 2002–2009. PLoS ONE 2013; 8: e56060.
Boyce M, van den Berg F, Mitchell T, et al. Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity. Eur J Clin Pharmacol. 2017; 73: 129–139.
Li Z, Wu C, Li L, et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol. 2017; 23: 222–228.
Cheung KS, Chan EW, Wong AY, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28–35.
Martin FC, Chenevix-Trench G, Yeomans ND, et al. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016; 44: 915–925.
Corsonello A, Lattanzio F, Bustacchini S. Adverse events of proton pump inhibitors: potential mechanisms. Curr Drug Metab. 2017 Dec 7. [Epub ahead of print]
Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013; 24: 1161–1168.
Lin SM, Yang SH, Liang CC, et al. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018; 29: 153–162.
Kumar S, Drake MT, Schleck C, et al. Incidence and predictors of osteoporotic fractures in patients with Barrett’s oesophagus: a population-based nested case-control study. Aliment Pharmacol Ther. 2017; 46: 1094–1102.
Targownik LE, Goertzen AL, Luo Y, et al. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017; 112: 95–101.
Cea-Soriano L, Johansson S, García Rodríguez LA. Risk factors for falls with use of acid-suppressive drugs. Epidemiology 2013; 24: 600–607.
Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 2013; 280: 5052–5064.
Abrahamsen B, Vestergaard P. Proton pump inhibitor use and fracture risk – effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. Bone 2013; 57: 269–271.
Hinson AM, Wilkerson BM, Rothman-Fitts I, et al. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015; 63: 2070–2073.
Nagy E. What do we know about the diagnostics, treatment and epidemiology of Clostridioides (Clostridium) difficile infection in Europe? J Infect Chemother. 2018; 24: 164–170.
Villafuerte-Gálvez JA, Kelly CP. Proton pump inhibitors and risk of Clostridium difficile infection: association or causation? Curr Opin Gastroenterol. 2018; 34: 11–18.
Naito Y, Kashiwagi K, Takagi T, et al. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion 2018; 97: 195–204.
McCarthy DM. Proton pump inhibitor use and Clostridium difficile colitis: cause or coincidence? J Clin Gastroenterol. 2012; 46: 350–353.
Takagi T, Naito Y, Inoue R, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018; 62: 100–105.
Hermos JA, Young MM, Fonda JR, et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis. 2012; 54: 33–42.
Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE 2015; 10: e0128004.
Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ 2016; 355: i5813.
Ayoub F, Lascano J, Morelli G. Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis. Gastroenterology Res. 2017; 10: 288–293.
Arai N, Nakamizo T, Ihara H, et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. PLoS ONE 2017; 12: e0169300.
Bateman BT, Bykov K, Choudhry NK, et al. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013; 347: f5416.
Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014; 86: 837–844.
Toth-Manikowski S, Grams ME. Proton pump inhibitors and kidney disease – GI upset for the nephrologist? Kidney Int Rep. 2017; 2: 297–301.
Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018; 33: 331–342.
Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016; 29: 611–616.
Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015; 265: 419–428.
Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016; 73: 410–416.
Fallahzadeh MK, Borhani Haghighi A, Namazi MR. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther. 2010; 35: 125–126.
Moayyedi P, Lewis MA. Proton pump inhibitors and dementia: deciphering the data. Am J Gastroenterol. 2017; 112: 1809–1811.
Zhu W, Hong K. Potential cardiovascular risks of proton pump inhibitors in the general population. Int Heart J. 2017; 58: 163–166.
Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE 2015; 10: e124653.
Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018; 27: 443–450.
Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14: 179.
Dahal K, Sharma SP, Kaur J, et al. Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials. Am J Ther. 2017; 24: e559–e569.
Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017; 33: 619–623.
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37: 201–211.